Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q3 2020 · 10-Q
Revenue$5.56M$5.56M−55.9% vs Q3 2019 Net Income-$3.16M-$3.16MN/M vs Q3 2019 EPS Diluted-$0.03-$0.03N/M vs Q3 2019 Gross Profit$2,458,000−70.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,728,000N/M Free Cash Flowderived-$2,016,000N/M Margins · derivedGross margin44.2%−22.7 pt vs Q3 2019
Operating margin-56.6%−42.6 pt vs Q3 2019
Net margin-56.7%−42.7 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 6, 2020 · 37 d after period end